SCHEMBL4851940

SCHEMBL4851940

COc1cc(C=O)ccc1OCc1nc(-c2ccccc2)cn1C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
HTT P42858 1/20 0.51
FDPS P14324 1/20 0.49
PDE10A Q9Y233 8/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TTR P02766 1/20 0.46
CYP2C9 P11712 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TSHR P16473 1/20 0.45
HPGD P15428 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850385 0.81 PDE10A (0.52) NPC1RAB9APDE10A
SCHEMBL4852679 0.78 PDE10A (0.42) ALDH1A1MAPTPDE10AMEN1KMT2A
SCHEMBL5935621 0.75 KDM4E (0.54) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL161066 0.74 ALDH1A1 (0.73) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6586658 0.72 ALDH1A1 (0.52) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6972867 0.72 ALDH1A1 (0.64) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL4854113 0.72 PPARD (0.53) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL4845955 0.72 ALDH1A1 (0.51) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6157314 0.72 ALDH1A1 (0.54) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL29954509 0.71 ALDH1A1 (0.60) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 ALDH1A1 821/4885MAPT 4700/4885SMN1; SMN2 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.